Article · Wikipedia archive · Last revised Jul 21, 2026

Dirozalkib

Dirozalkib is a drug that was developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer. It is an anaplastic lymphoma kinase inhibitor.

Last revised
Jul 21, 2026
Read time
≈ 1 min
Length
204 w
Citations
5
Source
Wikipedia ↗
Dirozalkib
Identifiers
  • 5-Chloro-2-N-(6-methyl-5-piperidin-4-yl-2,3-dihydro-1,4-benzodioxin-8-yl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC27H32ClN5O4S
Molar mass558.09 g·mol−1
3D model (JSmol)
  • CC1=CC(=C2C(=C1C3CCNCC3)OCCO2)NC4=NC=C(C(=N4)NC5=CC=CC=C5S(=O)(=O)C(C)C)Cl
  • InChI=1S/C27H32ClN5O4S/c1-16(2)38(34,35)22-7-5-4-6-20(22)31-26-19(28)15-30-27(33-26)32-21-14-17(3)23(18-8-10-29-11-9-18)25-24(21)36-12-13-37-25/h4-7,14-16,18,29H,8-13H2,1-3H3,(H2,30,31,32,33)
  • Key:ABKQZNVWMCRCGQ-UHFFFAOYSA-N

Dirozalkib is a drug that was developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer. It is an anaplastic lymphoma kinase inhibitor.1 234

It was approved for use in China in August of 2025.5

References

References

  1. "Dirozalkib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. Ai X, Guo R, Zhang L, Fang J, Zhang Y, Chen J, et al. (February 2026). "Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer". European Journal of Cancer. 235 116221. Oxford. doi:10.1016/j.ejca.2026.116221. PMID 41539180.
  3. Fang L, Jiang X, Song K, Shi P, Wang L, Xu L, et al. (December 2025). "Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)". Cancer Chemotherapy and Pharmacology. 95 (1): 122. doi:10.1007/s00280-025-04837-x. PMID 41348226.
  4. Basmajian K, Stepanyan Z, Sarkissian S (July 2026). "A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer". Anticancer Research. 46 (7): 3609–3618. doi:10.21873/anticanres.18227. PMID 42373241.
  5. S&P Capital IQ (22 August 2025). "The Innovative Drug Dirozalkib Tablets Independently Developed by Xuanzhu Biopharm Obtained Drug Registration Approval from NMPA". MarketScreener.